Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.65 |
| ▸ | ITGB3 | P05106 | 14/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.59 |
| ▸ | ITGB1 | P05556 | 13/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 13/20 | 0.53 |
| ▸ | ITGAV | P06756 | 11/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5769759 | 0.89 | PPARG (0.55) | PPARGITGB3ITGA2BITGB1ITGA5 | |
| SCHEMBL13475126 | 0.89 | PPARG (0.69) | PPARGITGB3ITGA2BITGB1ITGA5 | |
| SCHEMBL5738689 | 0.88 | PPARG (0.54) | PPARGITGB3ITGA2BITGB1ITGA5 | |
| SCHEMBL4874828 | 0.84 | PPARG (0.58) | PPARGITGB3ITGA2BITGB1ITGA5 | |
| Hydrochloric Acid SCHEMBL5738405 | 0.83 | PPARG (0.57) | PPARGITGB3ITGA2BITGB1ITGA5 | |
| SCHEMBL3313236 | 0.82 | PPARG (0.58) | PPARGITGB3ITGB1ITGA5ITGAV | |
| SCHEMBL13742843 | 0.81 | PPARG (0.54) | PPARGITGB3ITGB1ITGA5ITGAV | |
| SCHEMBL21422518 | 0.80 | PPARG (0.52) | PPARGITGB3ITGAVCYP3A4RXRA | |
| SCHEMBL2332479 | 0.80 | PPARA (0.61) | PPARG | |
| SCHEMBL2361274 | 0.80 | PPARA (0.61) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622898-A1 | PROCESSES FOR MAKING THIAZOLIDINEDIONE DERIVATIVES AND COMPOUNDS THEREOF | Synthon B.V. (NL) | 2006-02-08 | — | — | EP | disclosed |
| US-20050059708-A1 | Processes for making thiazolidinedione derivatives and compounds thereof | SYNTHON BV (NL) | 2005-03-17 | — | — | US | disclosed |
| WO-2004101560-A1 | PROCESSES FOR MAKING THIAZOLIDINEDIONE DERIVATIVES AND COMPOUNDS THEREOF | SYNTHON B.V. (NL) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059708-A1 | Processes for making thiazolidinedione derivatives and compounds thereof | PPARD, PPARG, PPARA | PPARG 2/4885ITGB3 2321/4885ITGA2B 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.